IDH1 and central nervous system cancer: In recent years, immunohistochemical data using antibodies specific to IDH1 R132H mutant protein have revealed a more widespread tumor cell distribution than expected, including in the remote contrahemisphere, and have redefined high-grade glioma as a whole-brain disease (20).